KDM1A and Ewing sarcoma: In vitro studies assaying the synergistic effect of LSD1 inhibitors with other chemotherapeutic agents in Ewing sarcoma showed synergy with cyclophosphamide, a DNA alkylating agent, and topotecan, a topoisomerase II inhibitor (105).